Inhibition of Cholesterol Synthesis by Green and Black Tea

绿茶和红茶抑制胆固醇合成

基本信息

  • 批准号:
    7701289
  • 负责人:
  • 金额:
    $ 18.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-01 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): "Functional foods", herbal and other botanical products, and nutritional supplements have gained great popularity among the public as safe and effective means to treat chronic and acute diseases. As hypercholesterolemia is a widespread problem for which there is great interest in alternative medicines, the demonstrated ability of black tea to decrease serum cholesterol levels is of particular interest. Similarly, green tea has been shown to be hypocholesterolemic in animal studies. The mechanism by which these safe and widely consumed beverages act to lower cholesterol has not yet been elucidated. Although most current evidence indicates that tea polyphenols reduce the absorption of dietary and biliary cholesterol, our recent studies with hepatoma cells indicate that green and black tea extracts also decrease cholesterol synthesis via both direct enzyme inhibition and by suppression of HMG-CoA reductase activity. Knowledge of how tea consumption lowers cholesterol levels is essential to understanding the benefits and potential adverse effects of its intake, particularly in combination with prescription pharmaceuticals, including the statin drugs, which similarly inhibit cholesterol synthesis at HMG-CoA reductase. As our current studies indicate that tea extracts cause the activation of AMP-kinase to suppress HMG-CoA reductase activity, the objectives of this application are to determine if tea extracts directly activate AMP-kinase, or if upstream signaling pathways are involved; and to determine if tea suppresses cholesterol synthesis in vivo. These studies should delineate the intracellular mechanism by which tea compounds suppress cholesterol synthesis, and elucidate the extent to which suppression of cholesterol synthesis contributes to the hypocholesterolemic effect of green and black tea. These studies should establish a solid, mechanistic understanding of how tea decreases cholesterol synthesis and lowers blood cholesterol levels, and, given the developing recognition of the role of AMP-kinase in diabetes, may also open new pathways to the management of diabetes and "metabolic syndrome".
描述(由申请人提供):“功能性食品”、草药和其他植物产品以及营养补充剂作为治疗慢性和急性疾病的安全有效手段,在公众中广受欢迎。由于高胆固醇血症是一个普遍存在的问题,因此对替代药物有很大的兴趣,红茶降低血清胆固醇水平的能力特别令人感兴趣。同样,绿色茶已被证明是低胆固醇的动物研究。这些安全和广泛消费的饮料降低胆固醇的机制尚未阐明。虽然目前大多数证据表明,茶多酚减少饮食和胆汁胆固醇的吸收,我们最近的研究与肝癌细胞表明,绿色和红茶提取物也减少胆固醇合成通过直接酶抑制和抑制HMG-CoA还原酶活性。了解茶叶消费如何降低胆固醇水平对于了解其摄入的益处和潜在的不良影响至关重要,特别是与处方药(包括他汀类药物)结合使用时,这些药物同样会抑制HMG-CoA还原酶的胆固醇合成。由于我们目前的研究表明,茶提取物引起AMP-激酶的激活以抑制HMG-CoA还原酶活性,因此本申请的目的是确定茶提取物是否直接激活AMP-激酶,或者是否涉及上游信号传导途径;并确定茶是否抑制体内胆固醇合成。这些研究应阐明茶化合物抑制胆固醇合成的细胞内机制,并阐明胆固醇合成的抑制在多大程度上有助于绿色和红茶的降胆固醇作用。这些研究应该建立一个坚实的,机械的理解如何茶减少胆固醇合成和降低血液胆固醇水平,并鉴于开发认识的作用,腺苷酸激酶在糖尿病中,也可能开辟新的途径来管理糖尿病和“代谢综合征”。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TODD D PORTER其他文献

TODD D PORTER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TODD D PORTER', 18)}}的其他基金

Inhibition of Cholesterol Synthesis by Green and Black Tea
绿茶和红茶抑制胆固醇合成
  • 批准号:
    7883660
  • 财政年份:
    2009
  • 资助金额:
    $ 18.14万
  • 项目类别:
Inhibition of Cholesterol Synthesis by Policosanol
普利醇对胆固醇合成的抑制
  • 批准号:
    7415194
  • 财政年份:
    2007
  • 资助金额:
    $ 18.14万
  • 项目类别:
Inhibition of Cholesterol Synthesis by Policosanol
普利醇对胆固醇合成的抑制
  • 批准号:
    7195943
  • 财政年份:
    2007
  • 资助金额:
    $ 18.14万
  • 项目类别:
AMES MUTAGENICITY TESTING WITH RECOMBINANT HUMAN P450S
使用重组人 P450S 进行 AMES 突变性测试
  • 批准号:
    2155288
  • 财政年份:
    1992
  • 资助金额:
    $ 18.14万
  • 项目类别:
AMES MUTAGENICITY TESTING WITH RECOMBINANT HUMAN P450S
使用重组人 P450S 进行 AMES 突变性测试
  • 批准号:
    2155287
  • 财政年份:
    1992
  • 资助金额:
    $ 18.14万
  • 项目类别:
AMES MUTAGENICITY TESTING WITH RECOMBINANT HUMAN P-450S
使用重组人 P-450S 进行 AMES 突变性测试
  • 批准号:
    3254685
  • 财政年份:
    1992
  • 资助金额:
    $ 18.14万
  • 项目类别:
AMES MUTAGENICITY TESTING WITH RECOMBINANT HUMAN P450S
使用重组人 P450S 进行 AMES 突变性测试
  • 批准号:
    2391600
  • 财政年份:
    1992
  • 资助金额:
    $ 18.14万
  • 项目类别:
HETEROLOGOUS EXPRESSION OF CYTOCHROME P-450
细胞色素 P-450 的异源表达
  • 批准号:
    2185074
  • 财政年份:
    1991
  • 资助金额:
    $ 18.14万
  • 项目类别:
HETEROLOGOUS EXPRESSION OF CYTOCHROME P-450
细胞色素 P-450 的异源表达
  • 批准号:
    3307102
  • 财政年份:
    1991
  • 资助金额:
    $ 18.14万
  • 项目类别:
HETEROLOGOUS EXPRESSION OF CYTOCHROME P-450
细胞色素 P-450 的异源表达
  • 批准号:
    3307101
  • 财政年份:
    1991
  • 资助金额:
    $ 18.14万
  • 项目类别:

相似海外基金

Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
  • 批准号:
    2867610
  • 财政年份:
    2023
  • 资助金额:
    $ 18.14万
  • 项目类别:
    Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
  • 批准号:
    BB/W009633/1
  • 财政年份:
    2022
  • 资助金额:
    $ 18.14万
  • 项目类别:
    Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2021
  • 资助金额:
    $ 18.14万
  • 项目类别:
    Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
  • 批准号:
    459043
  • 财政年份:
    2021
  • 资助金额:
    $ 18.14万
  • 项目类别:
    Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2020
  • 资助金额:
    $ 18.14万
  • 项目类别:
    Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10561642
  • 财政年份:
    2019
  • 资助金额:
    $ 18.14万
  • 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2019
  • 资助金额:
    $ 18.14万
  • 项目类别:
    Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
  • 批准号:
    2243045
  • 财政年份:
    2019
  • 资助金额:
    $ 18.14万
  • 项目类别:
    Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10359032
  • 财政年份:
    2019
  • 资助金额:
    $ 18.14万
  • 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
  • 批准号:
    428988
  • 财政年份:
    2019
  • 资助金额:
    $ 18.14万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了